Glitazones in the treatment of diabetes mellitus type 2: Executive summary of final report A05-05A, Version 1.0

The aims of this research were the comparative benefit assessments of long-term treatment with

1. pioglitazone or rosiglitazone vs. placebo,

2. pioglitazone or rosiglitazone vs. another glucose-lowering drug or non-drug intervention,

3. pioglitazone vs. rosiglitazone,

1. as monotherapy or in combination with another glucose-lowering therapy,

2. in patients with diabetes mellitus type 2 treated within the framework of the valid drug approval criteria.

The focus of the assessment was on patient-relevant therapy goals.

The benefit assessment was based on the comparison of desired and undesired effects of the individual drugs.